Amanda R Margolis1, Andrea L Porter1, Carla E Staresinic2, Cheryl A Ray2. 1. University of Wisconsin-Madison School of Pharmacy, Madison, WI, and William S. Middleton Memorial Veterans Hospital, Madison, WI. 2. William S. Middleton Memorial Veterans Hospital, Madison, WI.
Abstract
PURPOSE: To analyze the impact of a 12-week extended International Normalized Ratio (INR) follow-up interval on healthcare use. METHODS: A prospective cohort study of the use of an extended INR follow-up interval of up to 12 weeks was conducted over 2 years in a pharmacist-managed anticoagulation clinic. A detailed protocol was used to extend the INR follow-up interval to 5-6 weeks and then 7-8 weeks and 11-12 weeks. The number of planned and unplanned anticoagulation encounters, procedures requiring warfarin interruption, telephone triage phone calls, emergency department visits, and hospitalizations were collected. A post hoc subanalysis was also completed on participants who were scheduled for 4 consecutive 12-week intervals. RESULTS: Compared to baseline, at 12 months there was a mean decrease in planned anticoagulation encounters of 2.24 visits (p < 0.001) among 44 participants. From 12 to 24 months compared to baseline, there was a mean decrease in planned anticoagulation encounters of 3.13 visits (p < 0.001) and an increase of 0.54 unplanned anticoagulation encounters (p = 0.04) among 39 participants. The remainder of healthcare use variables were not statistically significantly different from baseline at any time point. Of the 15 participants scheduled for 4 consecutive 12-week intervals, there was a decrease from baseline of approximately 5 visits over the course of a year (p < 0.001). CONCLUSION: An extended INR follow-up interval appears to decrease anticoagulation healthcare use without an increase in acute healthcare use. While this intervention could be cost-effective, institutions need to consider safety, efficacy, and feasibility prior to implementation. Published by Oxford University Press on behalf of the American Society of Health-System Pharmacists 2019.
PURPOSE: To analyze the impact of a 12-week extended International Normalized Ratio (INR) follow-up interval on healthcare use. METHODS: A prospective cohort study of the use of an extended INR follow-up interval of up to 12 weeks was conducted over 2 years in a pharmacist-managed anticoagulation clinic. A detailed protocol was used to extend the INR follow-up interval to 5-6 weeks and then 7-8 weeks and 11-12 weeks. The number of planned and unplanned anticoagulation encounters, procedures requiring warfarin interruption, telephone triage phone calls, emergency department visits, and hospitalizations were collected. A post hoc subanalysis was also completed on participants who were scheduled for 4 consecutive 12-week intervals. RESULTS: Compared to baseline, at 12 months there was a mean decrease in planned anticoagulation encounters of 2.24 visits (p < 0.001) among 44 participants. From 12 to 24 months compared to baseline, there was a mean decrease in planned anticoagulation encounters of 3.13 visits (p < 0.001) and an increase of 0.54 unplanned anticoagulation encounters (p = 0.04) among 39 participants. The remainder of healthcare use variables were not statistically significantly different from baseline at any time point. Of the 15 participants scheduled for 4 consecutive 12-week intervals, there was a decrease from baseline of approximately 5 visits over the course of a year (p < 0.001). CONCLUSION: An extended INR follow-up interval appears to decrease anticoagulation healthcare use without an increase in acute healthcare use. While this intervention could be cost-effective, institutions need to consider safety, efficacy, and feasibility prior to implementation. Published by Oxford University Press on behalf of the American Society of Health-System Pharmacists 2019.
Entities:
Keywords:
International Normalized Ratio; anticoagulation; drug monitoring; health services; warfarin
Authors: Andrea L Porter; Amanda R Margolis; Rebecca R Schoen; Carla E Staresinic; Cheryl A Ray; Christopher D Fletcher Journal: J Thromb Thrombolysis Date: 2017-04 Impact factor: 2.300
Authors: Sherrie L Aspinall; Xinhua Zhao; Steven M Handler; Roslyn A Stone; Janine C Kosmoski; Elizabeth A Libby; Susan Dove Francis; David A Goodman; Rebecca D Roman; Heather L Bieber; Jennifer M Voisine; Sean M Jeffery; Charley A Hepfinger; Diane G Hagen; Micki M Martin; Joseph T Hanlon Journal: J Am Geriatr Soc Date: 2010-07-19 Impact factor: 5.562
Authors: G D Barnes; X Kong; D Cole; B Haymart; E Kline-Rogers; S Almany; M Dahu; M Ekola; S Kaatz; J Kozlowski; J B Froehlich Journal: J Thromb Haemost Date: 2018-06-06 Impact factor: 5.824
Authors: Nicholas W Carris; Andrew Y Hwang; Steven M Smith; James R Taylor; Karen Sando; Jason Powell; Eric I Rosenberg; Marc S Zumberg; John G Gums; Eric A Dietrich; Katherine Vogel Anderson Journal: J Thromb Thrombolysis Date: 2016-11 Impact factor: 2.300
Authors: Andrea L Porter; Amanda R Margolis; Carla E Staresinic; Michael W Nagy; Rebecca R Schoen; Cheryl A Ray; Christopher D Fletcher Journal: J Thromb Thrombolysis Date: 2019-02 Impact factor: 2.300
Authors: Greg Samsa; David B Matchar; Rowena J Dolor; Ingela Wiklund; Ewa Hedner; Gail Wygant; Ole Hauch; Cheryl Beadle Marple; Roger Edwards Journal: Health Qual Life Outcomes Date: 2004-05-06 Impact factor: 3.186
Authors: Yolima Puentes-Osorio; Pedro Amariles; Miguel Ángel Calleja; Vicente Merino; Juan Camilo Díaz-Coronado; Daniel Taborda Journal: Auto Immun Highlights Date: 2021-05-31